Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 21 | 2024 | 1084 | 2.330 |
Why?
|
| Heart Failure | 22 | 2025 | 2386 | 1.890 |
Why?
|
| Vascular Resistance | 3 | 2025 | 194 | 0.800 |
Why?
|
| Cardiac Rehabilitation | 1 | 2023 | 29 | 0.800 |
Why?
|
| Hypertension, Pulmonary | 4 | 2020 | 464 | 0.770 |
Why?
|
| Self Care | 1 | 2023 | 227 | 0.720 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2023 | 158 | 0.700 |
Why?
|
| Myocarditis | 1 | 2022 | 130 | 0.690 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2021 | 374 | 0.610 |
Why?
|
| Patient Care Team | 1 | 2023 | 572 | 0.600 |
Why?
|
| Acute Coronary Syndrome | 1 | 2022 | 244 | 0.590 |
Why?
|
| Transducers, Pressure | 1 | 2018 | 11 | 0.590 |
Why?
|
| Blood Pressure Monitors | 1 | 2018 | 5 | 0.580 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2018 | 43 | 0.570 |
Why?
|
| Stroke Volume | 3 | 2025 | 534 | 0.570 |
Why?
|
| Heart, Artificial | 1 | 2018 | 69 | 0.550 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 304 | 0.550 |
Why?
|
| Heart Transplantation | 4 | 2024 | 875 | 0.530 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 471 | 0.500 |
Why?
|
| Drug Overdose | 1 | 2017 | 73 | 0.500 |
Why?
|
| Pulmonary Artery | 4 | 2024 | 461 | 0.480 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 168 | 0.400 |
Why?
|
| Electrocardiography | 1 | 2017 | 989 | 0.350 |
Why?
|
| Ventricular Function, Left | 3 | 2024 | 545 | 0.290 |
Why?
|
| Humans | 36 | 2025 | 132348 | 0.280 |
Why?
|
| Thrombosis | 2 | 2022 | 529 | 0.250 |
Why?
|
| Homocysteine | 1 | 2005 | 120 | 0.230 |
Why?
|
| Prosthesis Implantation | 2 | 2024 | 153 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 903 | 0.220 |
Why?
|
| Treatment Outcome | 11 | 2024 | 13017 | 0.200 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 212 | 0.200 |
Why?
|
| Retrospective Studies | 17 | 2024 | 17364 | 0.200 |
Why?
|
| Renal Dialysis | 3 | 2022 | 889 | 0.200 |
Why?
|
| Cancer Care Facilities | 1 | 2022 | 38 | 0.200 |
Why?
|
| Renal Replacement Therapy | 2 | 2021 | 155 | 0.190 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2024 | 185 | 0.190 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 47 | 0.180 |
Why?
|
| Middle Aged | 16 | 2024 | 28891 | 0.180 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2023 | 107 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 667 | 0.180 |
Why?
|
| Hypothermia | 1 | 2021 | 65 | 0.180 |
Why?
|
| Hyponatremia | 1 | 2022 | 74 | 0.180 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2020 | 20 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 169 | 0.170 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 98 | 0.160 |
Why?
|
| Quality of Life | 4 | 2025 | 2151 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 339 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2020 | 57 | 0.160 |
Why?
|
| Plasmapheresis | 1 | 2019 | 33 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 65 | 0.160 |
Why?
|
| Palliative Care | 1 | 2023 | 457 | 0.150 |
Why?
|
| Pyridones | 1 | 2020 | 130 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2023 | 799 | 0.150 |
Why?
|
| Time Factors | 5 | 2024 | 6456 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 253 | 0.140 |
Why?
|
| Heparin | 1 | 2019 | 214 | 0.140 |
Why?
|
| Cardiology | 1 | 2023 | 497 | 0.140 |
Why?
|
| Male | 16 | 2024 | 65061 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 396 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 234 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 333 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2020 | 330 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2022 | 462 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2019 | 133 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 615 | 0.130 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 152 | 0.130 |
Why?
|
| Telemedicine | 1 | 2023 | 506 | 0.130 |
Why?
|
| Risk Factors | 6 | 2024 | 10911 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 99 | 0.130 |
Why?
|
| Mortality | 1 | 2018 | 257 | 0.130 |
Why?
|
| Reoperation | 1 | 2020 | 853 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3087 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 730 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 657 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 308 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 5010 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 256 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2018 | 860 | 0.110 |
Why?
|
| Female | 15 | 2024 | 70795 | 0.110 |
Why?
|
| Aged | 9 | 2024 | 21381 | 0.110 |
Why?
|
| Acute Disease | 1 | 2017 | 1176 | 0.100 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2013 | 32 | 0.100 |
Why?
|
| Hospitalization | 2 | 2019 | 1894 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5405 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 2062 | 0.100 |
Why?
|
| Adult | 8 | 2022 | 31619 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 212 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 217 | 0.090 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2012 | 41 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 461 | 0.090 |
Why?
|
| Hospital Mortality | 3 | 2023 | 1076 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 1165 | 0.090 |
Why?
|
| Angioplasty, Balloon | 1 | 2012 | 159 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 1867 | 0.090 |
Why?
|
| Young Adult | 3 | 2020 | 9945 | 0.080 |
Why?
|
| Incidence | 4 | 2019 | 3362 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3139 | 0.080 |
Why?
|
| Heart | 1 | 2013 | 699 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 2187 | 0.070 |
Why?
|
| Equipment Design | 2 | 2021 | 605 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 697 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 917 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2022 | 607 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2017 | 6540 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2005 | 62 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 440 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 1585 | 0.050 |
Why?
|
| Folic Acid | 1 | 2005 | 290 | 0.050 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2024 | 79 | 0.050 |
Why?
|
| United States | 4 | 2019 | 11628 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 311 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 57 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 7111 | 0.040 |
Why?
|
| Tracheostomy | 1 | 2023 | 201 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 51 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 179 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1353 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2020 | 90 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 359 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 127 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1570 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 180 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2018 | 133 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 656 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1247 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1126 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3710 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1229 | 0.030 |
Why?
|
| Medicare | 1 | 2018 | 448 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1153 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2017 | 781 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 569 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2012 | 38 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 58 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1068 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 20553 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 818 | 0.020 |
Why?
|
| Child | 1 | 2022 | 25827 | 0.010 |
Why?
|